Citations (76)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (12)
Emir Muzurović & Dimitri P Mikhailidis. (2020) Impact of glucagon-like peptide 1 receptor agonists and sodium-glucose transport protein 2 inhibitors on blood pressure and lipid profile. Expert Opinion on Pharmacotherapy 21:17, pages 2125-2135.
Read now
Read now
Katherine Merton, Michael J. Davies, Ujjwala Vijapurkar, Doreen Inman & Gary Meininger. (2018) Achieving the composite endpoint of HbA1c, body weight, and systolic blood pressure reduction with canagliflozin in patients with type 2 diabetes. Current Medical Research and Opinion 34:2, pages 313-318.
Read now
Read now
Rong Qiu, Dainius Balis, John Xie, Michael J. Davies, Mehul Desai & Gary Meininger. (2017) Longer-term safety and tolerability of canagliflozin in patients with type 2 diabetes: a pooled analysis. Current Medical Research and Opinion 33:3, pages 553-562.
Read now
Read now
Puneet Gupta & William B. White. (2017) Cardiovascular safety of therapies for type 2 diabetes. Expert Opinion on Drug Safety 16:1, pages 13-25.
Read now
Read now
Thomas C. Blevins & Azeez Farooki. (2017) Bone effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus. Postgraduate Medicine 129:1, pages 159-168.
Read now
Read now
Matthew R. Weir. (2016) The kidney and type 2 diabetes mellitus: therapeutic implications of SGLT2 inhibitors. Postgraduate Medicine 128:3, pages 290-298.
Read now
Read now
Jan N. Basile. (2016) A Multifactorial Approach to Reduce Cardiovascular Disease in Type 2 Diabetes Mellitus: Now More Than Ever. Hospital Practice 44:1, pages 9-20.
Read now
Read now
Vlado Perkovic, Meg Jardine, Ujjwala Vijapurkar & Gary Meininger. (2015) Renal effects of canagliflozin in type 2 diabetes mellitus. Current Medical Research and Opinion 31:12, pages 2219-2231.
Read now
Read now
Jochen Seufert. (2015) SGLT2 inhibitors – an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin. Diabetes, Metabolic Syndrome and Obesity 8, pages 543-554.
Read now
Read now
Lawrence Blonde, Vincent Woo, Chantal Mathieu, Jacqueline Yee, Ujjwala Vijapurkar, William Canovatchel & Gary Meininger. (2015) Achievement of treatment goals with canagliflozin in patients with type 2 diabetes mellitus: a pooled analysis of randomized controlled trials. Current Medical Research and Opinion 31:11, pages 1993-2000.
Read now
Read now
Jaime A. Davidson & Louis Kuritzky. (2014) Sodium Glucose Co-Transporter 2 Inhibitors and Their Mechanism for Improving Glycemia in Patients with Type 2 Diabetes. Postgraduate Medicine 126:6, pages 33-48.
Read now
Read now
Stephen Brunton & Timothy S. Reid. (2014) Canagliflozin, a Sodium Glucose Co-transporter 2 Inhibitor, for the Management of Type 2 Diabetes. Hospital Practice 42:3, pages 96-108.
Read now
Read now
Articles from other publishers (64)
Tanvi Patil, Morgan Cook, Jesse Hobson, Alamdeep Kaur & Aliza Lee. (2023) Evaluating the Safety of Sodium-Glucose Cotransporter-2 Inhibitors in a Nationwide Veterans Health Administration Observational Cohort Study. The American Journal of Cardiology 201, pages 281-293.
Crossref
Crossref
Sanobia Yousuf & Muhammad Yakoob Ahmedani. (2022) Efficacy and safety of empagliflozin in people with type 2 diabetes during Ramadan fasting. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 16:11, pages 102633.
Crossref
Crossref
Sumanth KHAKDE, Hafsa JAWAID, Farah YASMIN, Mashal BINTE ALI & Abdur REHMAN. (2022) Is there a paradigm shift in preventing diabetic heart failure? A review of SGLT2 inhibitors. Minerva Endocrinology 47:3.
Crossref
Crossref
Wajd Alkabbani, Arsène Zongo, Jasjeet K. Minhas-Sandhu, Dean T. Eurich, Baiju R. Shah, Mhd Wasem Alsabbagh & John-Michael Gamble. (2022) Sodium-Glucose Cotransporter-2 Inhibitors and Urinary Tract Infections: A Propensity Score–matched Population-based Cohort Study. Canadian Journal of Diabetes 46:4, pages 392-403.e13.
Crossref
Crossref
Gang Chen, Xiaolin Li, Quexuan Cui, Yangzhong Zhou, Bin Zhao, Dan Mei & Xuemei. (2022) Acute kidney injury following SGLT2 inhibitors among diabetic patients: a pharmacovigilance study. International Urology and Nephrology 54:11, pages 2949-2957.
Crossref
Crossref
Yi-Hsuan Lin, Chia-Hung Lin, Yu-Yao Huang, An-Shun Tai, Shih-Chen Fu, Szu-Tah Chen & Sheng-Hsuan Lin. (2022) Risk factors of first and recurrent genitourinary tract infection in patients with type 2 diabetes treated with SGLT2 inhibitors: A retrospective cohort study. Diabetes Research and Clinical Practice 186, pages 109816.
Crossref
Crossref
Jie Yu, Jingwei Li, Phillip J Leaver, Clare Arnott, Mark D Huffman, Jacob A Udell, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, David R Matthews, Wayne Shaw, Norman Rosenthal, Bruce Neal & Gemma A Figtree. (2022)
Effects of canagliflozin on myocardial infarction: a
post hoc
analysis of the CANVAS programme and CREDENCE trial
. Cardiovascular Research 118:4, pages 1103-1114.
Crossref
Crossref
M. V. Shestakova, A. S. Ametov, M. B. Antsiferov, T. P. Bardymova, F. V. Valeeva, G. R. Galstyan, T. Yu. Demidova, I. A. Karpova, T. P. Kiseleva, A. Yu. Mayorov, A. M. Mkrtumyan, S. V. Nedogoda, N. А. Petunina, L. A. Ruyatkina, L. A. Suplotova, O. Yu. Sukhareva, V. V. Fadeev & M. S. Shamkhalova. (2022) Canagliflozin: from glycemic control to improvement of cardiovascular and renal prognosis in patients with type 2 diabetes mellitus. Resolution of Advisory Board. Diabetes mellitus 24:5, pages 479-486.
Crossref
Crossref
Mohamed A. Morsy, Hanaa M. Khalaf, Rehab A. Rifaai, Asmaa M.A. Bayoumi, Esraa M.M.A. Khalifa & Yasmine F. Ibrahim. (2021) Canagliflozin, an SGLT-2 inhibitor, ameliorates acetic acid-induced colitis in rats through targeting glucose metabolism and inhibiting NOX2. Biomedicine & Pharmacotherapy 141, pages 111902.
Crossref
Crossref
Daniele Scoccimarro, Giacomo Cipani, Ilaria Dicembrini & Edoardo Mannucci. (2021) Cigarette Smoking as a Predictor of Sodium–Glucose Cotransporter 2 Inhibitor–Associated Genital Infections: A Retrospective Cohort Study. Diabetes Care 44:6, pages e127-e128.
Crossref
Crossref
Jawad H. Butt, Kieran F. Docherty, Mark C. Petrie, Morten Schou, Mikhail N. Kosiborod, Eileen O’Meara, Tzvetana Katova, Charlotta E. A. Ljungman, Mirta Diez, Modele O. Ogunniyi, Anna Maria Langkilde, Mikaela Sjöstrand, Daniel Lindholm, Olof Bengtsson, Felipe A. Martinez, Piotr Ponikowski, Marc S. Sabatine, Scott D. Solomon, Pardeep S. Jhund, John J. V. McMurray & Lars Køber. (2021) Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction. JAMA Cardiology 6:6, pages 678.
Crossref
Crossref
Matthew R Weir, April Slee, Tao Sun, Dainius Balis, Richard Oh, Dick de Zeeuw & Vlado Perkovic. (2021) Effects of canagliflozin on serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program. Clinical Kidney Journal 14:5, pages 1396-1402.
Crossref
Crossref
Sutthichai Sae-Tia & Bettina C. Fries. 2021. Encyclopedia of Mycology. Encyclopedia of Mycology
719
725
.
Richard Pratley, Samuel Dagogo‐Jack, Bernard Charbonnel, Shrita Patel, Anne Hickman, Jie Liu, Lisa Tarasenko, Annpey Pong, Misoo C. Ellison, Susan Huyck, Ira Gantz & Steven G. Terra. (2020)
Efficacy and safety of ertugliflozin in older patients with type 2 diabetes: A pooled analysis of phase
III
studies
. Diabetes, Obesity and Metabolism 22:12, pages 2276-2286.
Crossref
Crossref
Srikanth Yandrapalli, Aaqib Malik, Adam Horblitt, Gayatri Pemmasani, Wilbert S. Aronow & William H. Frishman. (2020) Cardiovascular Safety and Benefits of Noninsulin Antihyperglycemic Drugs for the Treatment of Type 2 Diabetes Mellitus: Part 2. Cardiology in Review 28:5, pages 219-235.
Crossref
Crossref
Shrita Patel, Anne Hickman, Robert Frederich, Susan Johnson, Susan Huyck, James P. Mancuso, Ira Gantz & Steven G. Terra. (2020) Safety of Ertugliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Seven Phase 3 Randomized Controlled Trials. Diabetes Therapy 11:6, pages 1347-1367.
Crossref
Crossref
Jaspreet Kalra, Suresh Babu Mangali, Deepika Dasari, Audesh Bhat, Srashti Goyal, Indu Dhar, Dharamrajan Sriram & Arti Dhar. (2019) SGLT1 inhibition boon or bane for diabetes‐associated cardiomyopathy. Fundamental & Clinical Pharmacology 34:2, pages 173-188.
Crossref
Crossref
Salvatore Carbone & Dave L. Dixon. (2019) The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus. Cardiovascular Diabetology 18:1.
Crossref
Crossref
Vishal Gupta, Michael Willis, Pierre Johansen, Andreas Nilsson, Manan Shah, Amey Mane & Cheryl Neslusan. (2019) Long-Term Clinical Benefits of Canagliflozin 100 mg Versus Sulfonylurea in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin in India. Value in Health Regional Issues 18, pages 65-73.
Crossref
Crossref
Brecht Claerhout, Dipak Kalra, Christina Mueller, Gurparkash Singh, Nadir Ammour, Laura Meloni, Juuso Blomster, Mark Hopley, George Kafatos, Almenia Garvey, Peter Kuhn, Martine Lewi, Bart Vannieuwenhuyse, Benoît Marchal, Ketan Patel, Christoph Schindler & Mats Sundgren. (2019) Federated electronic health records research technology to support clinical trial protocol optimization: Evidence from EHR4CR and the InSite platform. Journal of Biomedical Informatics 90, pages 103090.
Crossref
Crossref
Maswood M. Ahmad, Imad Addin Brema & Mussa H. Almalki. 2019. Type 2 Diabetes [Working Title]. Type 2 Diabetes [Working Title].
Michael J. Davies, Katherine Merton, Ujjwala Vijapurkar, Jacqueline Yee & Rong Qiu. (2017) Efficacy and safety of canagliflozin in patients with type 2 diabetes based on history of cardiovascular disease or cardiovascular risk factors: a post hoc analysis of pooled data. Cardiovascular Diabetology 16:1.
Crossref
Crossref
Michael Pfeifer, Raymond R. Townsend, Michael J. Davies, Ujjwala Vijapurkar & Jimmy Ren. (2017) Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis. Cardiovascular Diabetology 16:1.
Crossref
Crossref
Mohamed Hassanein, Akram Echtay, Ahmed Hassoun, Monira Alarouj, Bachar Afandi, Raffi Poladian, Abdullah Bennakhi, Maciej Nazar, Paul Bergmans, Sofia Keim, Gill Hamilton & Sami T. Azar. (2017) Tolerability of canagliflozin in patients with type 2 diabetes mellitus fasting during Ramadan: Results of the Canagliflozin in Ramadan Tolerance Observational Study (CRATOS). International Journal of Clinical Practice 71:10, pages e12991.
Crossref
Crossref
Emma D. Deeks & André J. Scheen. (2017) Canagliflozin: A Review in Type 2 Diabetes. Drugs 77:14, pages 1577-1592.
Crossref
Crossref
Huilin Tang, Dandan Li, Jingjing Zhang, Yufeng Li, Tiansheng Wang, Suodi Zhai & Yiqing Song. (2017) Sodium-glucose co-transporter-2 inhibitors and risk of adverse renal outcomes among patients with type 2 diabetes: A network and cumulative meta-analysis of randomized controlled trials. Diabetes, Obesity and Metabolism 19:8, pages 1106-1115.
Crossref
Crossref
Richard E. Pratley & Eugenio Cersosimo. (2017) Use of Canagliflozin in Combination With and Compared to Incretin-Based Therapies in Type 2 Diabetes. Clinical Diabetes 35:3, pages 141-153.
Crossref
Crossref
Mehul Desai, Yshai Yavin, Dainius Balis, Don Sun, John Xie, William Canovatchel & Norm Rosenthal. (2017) Renal safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism 19:6, pages 897-900.
Crossref
Crossref
Matthew J. Budoff & John P. H. Wilding. (2017) Effects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus. International Journal of Clinical Practice 71:5, pages e12948.
Crossref
Crossref
George Grunberger. (2017) Should Side Effects Influence the Selection of Antidiabetic Therapies in Type 2 Diabetes?. Current Diabetes Reports 17:4.
Crossref
Crossref
Hermann Koepsell. (2017) The Na+-D-glucose cotransporters SGLT1 and SGLT2 are targets for the treatment of diabetes and cancer. Pharmacology & Therapeutics 170, pages 148-165.
Crossref
Crossref
Rhona Johnston, Olalekan Uthman, Ewen Cummins, Christine Clar, Pamela Royle, Jill Colquitt, Bee Kang Tan, Andrew Clegg, Saran Shantikumar, Rachel Court, J Paul O’Hare, David McGrane, Tim Holt & Norman Waugh. (2017) Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation. Health Technology Assessment 21:2, pages 1-218.
Crossref
Crossref
Jaime A. Davidson & Lance Sloan. (2016) Fixed-Dose Combination of Canagliflozin and Metformin for the Treatment of Type 2 Diabetes: An Overview. Advances in Therapy 34:1, pages 41-59.
Crossref
Crossref
Paul D. Rosenblit. (2016) Common medications used by patients with type 2 diabetes mellitus: what are their effects on the lipid profile?. Cardiovascular Diabetology 15:1.
Crossref
Crossref
Charmi A. Patel, Robert A. Bailey, Ujjwala Vijapurkar, Gary Meininger & Lawrence Blonde. (2016) A post-hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes-related quality measures. BMC Health Services Research 16:1.
Crossref
Crossref
D. R. Matthews, B. Zinman, C. Tong, G. Meininger & D. Polidori. (2016) Glycaemic efficacy of canagliflozin is largely independent of baseline β-cell function or insulin sensitivity. Diabetic Medicine 33:12, pages 1744-1747.
Crossref
Crossref
Wei Xiong, Ming Yue Xiao, Mei Zhang & Fei Chang. (2016) Efficacy and safety of canagliflozin in patients with type 2 diabetes. Medicine 95:48, pages e5473.
Crossref
Crossref
M. Rizzi & R. Trevisan. (2016) Genitourinary infections in diabetic patients in the new era of diabetes therapy with sodium-glucose cotransporter-2 inhibitors. Nutrition, Metabolism and Cardiovascular Diseases 26:11, pages 963-970.
Crossref
Crossref
Raymond R. Townsend, Israel Machin, Jimmy Ren, Angelina Trujillo, Masato Kawaguchi, Ujjwala Vijapurkar, C. V. Damaraju & Michael Pfeifer. (2016) Response to Stavropoulos. The Journal of Clinical Hypertension 18:10, pages 1074-1075.
Crossref
Crossref
Mathew John, Sonia Cerdas, Rafael Violante, Chaicharn Deerochanawong, Mohamed Hassanein, April Slee, William Canovatchel & Gill Hamilton. (2016) Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus living in hot climates. International Journal of Clinical Practice 70:9, pages 775-785.
Crossref
Crossref
Sanjay Kalra, Vikram Singh & Dinesh Nagrale. (2016) Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review. Advances in Therapy 33:9, pages 1502-1518.
Crossref
Crossref
H. W. Rodbard, J. Seufert, N. Aggarwal, A. Cao, A. Fung, M. Pfeifer & M. Alba. (2016) Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin. Diabetes, Obesity and Metabolism 18:8, pages 812-819.
Crossref
Crossref
Atsunori Kashiwagi, Satoshi Yoshida, Ichiro Nakamura, Kenichi Kazuta, Eiji Ueyama, Hideyuki Takahashi, Hayato Satomi, Yoshinori Kosakai & Kosei Kawamuki. (2016) Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes stratified by body mass index: A subgroup analysis of five randomized clinical trials. Journal of Diabetes Investigation 7:4, pages 544-554.
Crossref
Crossref
Pamela Kushner. (2016) Benefits/Risks of Sodium–Glucose Co-Transporter 2 Inhibitor Canagliflozin in Women for the Treatment of Type 2 Diabetes. Women's Health 12:3, pages 379-388.
Crossref
Crossref
Richard E. Gilbert, Matthew R. Weir, Paola Fioretto, Gordon Law, Mehul Desai, Irina Kline, Wayne Shaw & Gary Meininger. (2016) Impact of Age and Estimated Glomerular Filtration Rate on the Glycemic Efficacy and Safety of Canagliflozin: A Pooled Analysis of Clinical Studies. Canadian Journal of Diabetes 40:3, pages 247-257.
Crossref
Crossref
Alan J. Sinclair, Bruce Bode, Stewart Harris, Ujjwala Vijapurkar, Wayne Shaw, Mehul Desai & Gary Meininger. (2016) Efficacy and Safety of Canagliflozin in Individuals Aged 75 and Older with Type 2 Diabetes Mellitus: A Pooled Analysis. Journal of the American Geriatrics Society 64:3, pages 543-552.
Crossref
Crossref
L.A. Leiter, T. Forst, D. Polidori, D.A. Balis, J. Xie & S. Sha. (2016) Effect of canagliflozin on liver function tests in patients with type 2 diabetes. Diabetes & Metabolism 42:1, pages 25-32.
Crossref
Crossref
Joshua A. Levine, Amy Ann Lo, Amisha Wallia, Melinda Rogers & Lisa B. Van Wagner. (2016) Dapagliflozin-Induced Acute-on-Chronic Liver Injury. ACG Case Reports Journal 3:1, pages e169.
Crossref
Crossref
Robert R. Henry, Payal Thakkar, Cindy Tong, David Polidori & Maria Alba. (2015) Efficacy and Safety of Canagliflozin, a Sodium–Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes. Diabetes Care 38:12, pages 2258-2265.
Crossref
Crossref
Christian Mende. (2015) Management of Chronic Kidney Disease: The Relationship Between Serum Uric Acid and Development of Nephropathy. Advances in Therapy 32:12, pages 1177-1191.
Crossref
Crossref
Norm Rosenthal, Gary Meininger, Kirk Ways, David Polidori, Mehul Desai, Rong Qiu, Maria Alba, Frank Vercruysse, Dainius Balis, Wayne Shaw, Robert Edwards, Scott Bull, Nicholas Di Prospero, Sue Sha, Paul Rothenberg, William Canovatchel & Keith Demarest. (2015) Canagliflozin: a sodium glucose co‐transporter 2 inhibitor for the treatment of type 2 diabetes mellitus. Annals of the New York Academy of Sciences 1358:1, pages 28-43.
Crossref
Crossref
Damayanthi Devineni & David Polidori. (2015) Clinical Pharmacokinetic, Pharmacodynamic, and Drug–Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor. Clinical Pharmacokinetics 54:10, pages 1027-1041.
Crossref
Crossref
L. J. Gray, J. Dales, E. M. Brady, K. Khunti, W. Hanif & M. J. Davies. (2015) Safety and effectiveness of non-insulin glucose-lowering agents in the treatment of people with type 2 diabetes who observe Ramadan: a systematic review and meta-analysis. Diabetes, Obesity and Metabolism 17:7, pages 639-648.
Crossref
Crossref
Xia Chen, Pei Hu, Nicole Vaccaro, David Polidori, Christopher R. Curtin, Hans Stieltjes, Sue Sha, Sveta Weiner & Damayanthi Devineni. (2015) Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Canagliflozin in Healthy Chinese Subjects. Clinical Therapeutics 37:7, pages 1483-1492.e1.
Crossref
Crossref
Luc Van Gaal & André Scheen. (2015) Weight Management in Type 2 Diabetes: Current and Emerging Approaches to Treatment. Diabetes Care 38:6, pages 1161-1172.
Crossref
Crossref
Gary Meininger, William Canovatchel, David Polidori & Norm Rosenthal. (2015) Canagliflozin for the treatment of adults with Type 2 diabetes. Diabetes Management 5:3, pages 183-201.
Crossref
Crossref
M. J. Davies, A. Trujillo, U. Vijapurkar, C. V. Damaraju & G. Meininger. (2015) Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism 17:4, pages 426-429.
Crossref
Crossref
John P.H. Wilding, Lawrence Blonde, Lawrence A. Leiter, Sonia Cerdas, Cindy Tong, Jacqueline Yee & Gary Meininger. (2015) Efficacy and safety of canagliflozin by baseline HbA1c and known duration of type 2 diabetes mellitus. Journal of Diabetes and its Complications 29:3, pages 438-444.
Crossref
Crossref
Bruce Neal, Vlado Perkovic, Dick de Zeeuw, Kenneth W. Mahaffey, Greg Fulcher, Kirk Ways, Mehul Desai, Wayne Shaw, George Capuano, Maria Alba, Joel Jiang, Frank Vercruysse, Gary Meininger & David Matthews. (2015) Efficacy and Safety of Canagliflozin, an Inhibitor of Sodium–Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 Diabetes. Diabetes Care 38:3, pages 403-411.
Crossref
Crossref
B. Bode, K. Stenlöf, S. Harris, D. Sullivan, A. Fung, K. Usiskin & G. Meininger. (2015) Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes. Diabetes, Obesity and Metabolism 17:3, pages 294-303.
Crossref
Crossref
Curtis TriplittSusan Cornell. (2015) Canagliflozin Treatment in Patients with Type 2 Diabetes Mellitus. Clinical Medicine Insights: Endocrinology and Diabetes 8, pages CMED.S31526.
Crossref
Crossref
Virginia Valentine & Deborah Hinnen. (2015) Clinical Implications of Canagliflozin Treatment in Patients With Type 2 Diabetes. Clinical Diabetes 33:1, pages 5-13.
Crossref
Crossref
Korinne M. Piccolo & Joseph I. Boullata. 2015. Preventive Nutrition. Preventive Nutrition
83
113
.
Matthew R. Weir, Andrzej Januszewicz, Richard E. Gilbert, Ujjwala Vijapurkar, Irina Kline, Albert Fung & Gary Meininger. (2014) Effect of Canagliflozin on Blood Pressure and Adverse Events Related to Osmotic Diuresis and Reduced Intravascular Volume in Patients With Type 2 Diabetes Mellitus. The Journal of Clinical Hypertension 16:12, pages 875-882.
Crossref
Crossref